JP2024516037A5 - - Google Patents
Info
- Publication number
- JP2024516037A5 JP2024516037A5 JP2023567924A JP2023567924A JP2024516037A5 JP 2024516037 A5 JP2024516037 A5 JP 2024516037A5 JP 2023567924 A JP2023567924 A JP 2023567924A JP 2023567924 A JP2023567924 A JP 2023567924A JP 2024516037 A5 JP2024516037 A5 JP 2024516037A5
- Authority
- JP
- Japan
- Prior art keywords
- therapeutic agent
- inhibitor
- patient
- solvate
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163184685P | 2021-05-05 | 2021-05-05 | |
| US63/184,685 | 2021-05-05 | ||
| US202263320997P | 2022-03-17 | 2022-03-17 | |
| US63/320,997 | 2022-03-17 | ||
| PCT/US2022/027696 WO2022235817A1 (en) | 2021-05-05 | 2022-05-04 | Combination therapies comprising shp2 inhibitors and pd-1 inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024516037A JP2024516037A (ja) | 2024-04-11 |
| JP2024516037A5 true JP2024516037A5 (enExample) | 2025-05-14 |
Family
ID=83932910
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023567924A Pending JP2024516037A (ja) | 2021-05-05 | 2022-05-04 | Ｓｈｐ２阻害剤とｐｄ－１阻害剤とを含む併用療法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US12097203B2 (enExample) |
| EP (1) | EP4334318A4 (enExample) |
| JP (1) | JP2024516037A (enExample) |
| AU (1) | AU2022271243A1 (enExample) |
| CA (1) | CA3217084A1 (enExample) |
| IL (1) | IL308222A (enExample) |
| MX (1) | MX2023013064A (enExample) |
| WO (1) | WO2022235817A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2023012929A (es) * | 2021-05-05 | 2023-11-13 | Huyabio Int Llc | Terapias de combinacion que comprenden inhibidores de shp2 e inhibidores de tirosina cinasa egfr. |
| CN121013721A (zh) * | 2022-11-23 | 2025-11-25 | 沪亚生物国际有限公司 | 包含kras抑制剂和sph2抑制剂的组合疗法 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3517B1 (ar) | 2014-01-17 | 2020-07-05 | Novartis Ag | ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2 |
| WO2015107494A1 (en) | 2014-01-17 | 2015-07-23 | Novartis Ag | 1 -(triazin-3-yi_/pyridazin-3-yl)-piper(-azine)idine derivatives and compositions thereof for inhibiting the activity of shp2 |
| WO2016203406A1 (en) | 2015-06-19 | 2016-12-22 | Novartis Ag | Compounds and compositions for inhibiting the activity of shp2 |
| WO2017210134A1 (en) | 2016-05-31 | 2017-12-07 | Board Of Regents, University Of Texas System | Heterocyclic inhibitors of ptpn11 |
| KR102218333B1 (ko) | 2016-06-07 | 2021-02-22 | 자코바이오 파마슈티칼스 컴퍼니 리미티드 | Shp2 억제제로서 유용한 신규한 헤테로환형 유도체 |
| PT3468972T (pt) * | 2016-06-14 | 2020-08-21 | Novartis Ag | Compostos e composições para inibir a atividade da shp2 |
| IL311645B2 (en) | 2016-07-12 | 2025-11-01 | Revolution Medicines Inc | 2,5- disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines asallosteric shp2 inhibitors |
| CN110730678B (zh) | 2017-01-10 | 2022-07-15 | 诺华股份有限公司 | 包含alk抑制剂和shp2抑制剂的药物组合 |
| SG11201908820VA (en) | 2017-03-23 | 2019-10-30 | Jacobio Pharmaceuticals Co Ltd | Novel heterocyclic derivatives useful as shp2 inhibitors |
| TWI852912B (zh) | 2017-09-07 | 2024-08-21 | 美商銳新醫藥公司 | Shp2抑制劑組合物以及治療癌症的方法 |
| BR112020007058A2 (pt) | 2017-10-12 | 2020-10-06 | Revolution Medicines, Inc. | compostos de piridina, pirazina, e triazina como inibidores de shp2 alostéricos |
| WO2019126736A1 (en) | 2017-12-21 | 2019-06-27 | New York University | Pd-1 related cancer therapy |
| WO2019152454A1 (en) | 2018-01-30 | 2019-08-08 | Research Development Foundation | Shp2 inhibitors and methods of use thereof |
| RU2020133727A (ru) | 2018-03-21 | 2022-04-21 | Сучжоу Пухе Биофарма Ко., Лтд. | Ингибиторы shp2 и их применение |
| KR20200143417A (ko) | 2018-04-10 | 2020-12-23 | 레볼루션 메디슨즈, 인크. | Shp2 억제제 조성물, 암을 치료하는 방법 및 shp2 돌연변이를 갖는 대상체를 확인하는 방법 |
| JP2022508651A (ja) * | 2018-10-08 | 2022-01-19 | レヴォリューション・メディスンズ，インコーポレイテッド | 癌を処置するためのｓｈｐ２阻害剤組成物および方法 |
| EP3923940B1 (en) | 2019-02-12 | 2025-12-03 | Novartis AG | Pharmaceutical combination comprising tno155 and a pd-1 inhibitor |
| CN111647000B (zh) * | 2019-03-04 | 2021-10-12 | 勤浩医药（苏州）有限公司 | 吡嗪类衍生物及其在抑制shp2中的应用 |
| CN114502165A (zh) | 2019-09-23 | 2022-05-13 | 苏州浦合医药科技有限公司 | Shp2抑制剂及其用途 |
-
2022
- 2022-05-04 CA CA3217084A patent/CA3217084A1/en active Pending
- 2022-05-04 MX MX2023013064A patent/MX2023013064A/es unknown
- 2022-05-04 IL IL308222A patent/IL308222A/en unknown
- 2022-05-04 WO PCT/US2022/027696 patent/WO2022235817A1/en not_active Ceased
- 2022-05-04 EP EP22799520.6A patent/EP4334318A4/en not_active Withdrawn
- 2022-05-04 AU AU2022271243A patent/AU2022271243A1/en active Pending
- 2022-05-04 JP JP2023567924A patent/JP2024516037A/ja active Pending
- 2022-05-04 US US17/736,879 patent/US12097203B2/en active Active